Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beckman troponin assay delays

This article was originally published in The Gray Sheet

Executive Summary

Beckman Coulter plans to submit two 510(k)s in the first half of 2011 for its embattled cardiac troponin assay after completing prospective clinical trials to support the submissions, the firm disclosed in a May 14 Securities and Exchange Commission filing. Last month, Beckman removed from the U.S. market its AccuTn1 troponin kits used on its Unicel DxI platform and restricted distribution of the kits for use on its Access platform after FDA identified modifications the firm had made to the assay without proper clearance (1"The Gray Sheet" April 19, 2010). "The timing of the re-submission is worse than expected, extending headwinds into 2011," writes David Lewis, a Morgan Stanley analyst, in a May 14 report
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028870

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel